HER2-positive metastatic breast cancer

June 7, 2019

Long-term Data Continue to Support Perjeta Regimen for HER2-positive Metastatic Breast Cancer

News

End-of-study data from the CLEOPATRA trial supports the long-term efficacy of Genentech‘s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy for patients with previously untreated HER2-positive metastatic breast cancer. Patients on the ... Read more

June 8, 2017July 11, 2019

Response to Neratinib and Xeloda Combo Seen in Breast Cancer Patients with Brain Metastasis

News

Combining Puma Biotechnology’s candidate therapy PB272, also known as neratinib, with the chemotherapy drug Xeloda (capecitabine) appears to have therapeutic potential for patients with advanced HER2-positive breast cancer and brain metastasis, who were not previously treated with ... Read more

August 23, 2016August 23, 2016

Kadcycla Effective in Advanced Breast Cancer Patients Already Given Perjeta

News

Kadcyla (ado-trastuzumab emtansine, or T-DM1) may benefit HER2-positive metastatic breast cancer patients whose disease continues to progress despite prior treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab), according to the results ... Read more

October 2, 2014October 2, 2014

Genentech’s Perjeta Combination Therapy Effective for Aggressive Breast Cancer

Breast Cancer News, News

Newly released data from Genentech’s international phase 3 CLEOPATRA study demonstrates the efficacy of Perjeta treatment in patients with previously untreated HER2-positive metastatic breast cancer. Patient survival was extended by ... Read more